News

TAK-935 has successfully completed several Phase 1 clinical studies under Takeda’s leadership and will be moving into Phase 1b/2a clinical studies in rare epileptic encephalopathies where patients continue

Boehringer Ingelheim Therapeutic Area Biosimilars senior vice president and head Ivan Blanarik said: “We believe that if approved, BI 695501 can provide a valuable treatment option for the

Under the terms of the deal, which is anticipated to close by the end of the first quarter of this year, Lilly will pay $46.50 a share for

Suliqua is authorized for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral

The deal, which gives Biogen a license to Forward Pharma’s intellectual property, could help the US company extend the life of Tecfidera. Under several circumstances outlined in the deal, Biogen will

Niraparib is being made available for eligible women in the U.S. with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to

The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients

The trial’s original objective was the effect on progression-free survival (PFS) but the company has now added overall survival (OS), both for the combination and durvalumab monotherapy. The

The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005. The complaint was filed in the United States District Court